Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain-Reference-Cited by-同舟云学术

Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain

Published:2022-10 Issue: Volume:121 Page:106900
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Da Jennifer L.W.,Merker Vanessa L.,Jordan Justin T.,Ly K. Ina,Muzikansky Alona,Parsons Michael,Wolters Pamela L.,Xu Lei,Styren Scot,Brown Mark T.,Plotkin Scott R.

Funder

Children's Tumor Foundation

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference34 articles.

1. Schwannomatosis: a genetic and epidemiological study;Evans;J. Neurol. Neurosurg. Psychiatry,2018

2. The molecular pathogenesis of schwannomatosis, a paradigm for the co-involvement of multiple tumour suppressor genes in tumorigenesis;Kehrer-Sawatzki;Hum. Genet.,2017

3. Schwannomatosis;Dhamija,1993

4. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature;Sargen;Br. J. Dermatol.,2016

5. DGCR8 and the six hit, three-step model of schwannomatosis;Nogue;Acta Neuropathol.,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Features of course of pain syndrome in patients with schwannomatosis;S.S. Korsakov Journal of Neurology and Psychiatry;2024

2. New Targets for Cancer Pain Relief;Interdisciplinary Cancer Research;2024

3. Schwannomatosis: a Realm Reborn: year one;Current Opinion in Oncology;2023-09-01

4. Pharmacological management of cancer pain: Novel therapeutics;Biomedicine & Pharmacotherapy;2022-12